Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Grossman, M. Krabak (1999)
Leptomeningeal carcinomatosis.Cancer treatment reviews, 25 2
S. Schuster, M. Bishop, C. Tam, E. Waller, P. Borchmann, J. Mcguirk, U. Jäger, S. Jaglowski, C. Andreadis, J. Westin, I. Fleury, V. Bachanova, R. Foley, Joy Ho, S. Mielke, J. Magenau, H. Holte, Serafino Pantano, L. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. Maziarz (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell LymphomaThe New England Journal of Medicine, 380
(2020)
CD19/CD22 Dual-Targeted CAR-T Therapy Active in Relapsed/Refractory DLBCL.The oncologist
S. Neelapu (2019)
Managing the toxicities of CAR T‐cell therapyHematological Oncology, 37
Amber King, Jennifer Orozco (2019)
Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell LymphomaJournal of the Advanced Practitioner in Oncology, 10
F. Locke, A. Ghobadi, C. Jacobson, D. Miklos, L. Lekakis, O. Oluwole, Yi Lin, I. Braunschweig, B. Hill, J. Timmerman, A. Deol, P. Reagan, P. Stiff, I. Flinn, U. Farooq, A. Goy, P. Mcsweeney, J. Muñoz, T. Siddiqi, J. Chavez, A. Herrera, N. Bartlett, J. Wiezorek, L. Navale, A. Xue, Yi-zhou Jiang, A. Bot, J. Rossi, Jenny Kim, W. Go, S. Neelapu (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.The Lancet. Oncology, 20 1
T. Siddiqi, Xiuli Wang, J. Palmer, L. Popplewell, L. Nikolaenko, A. Herrera, L. Budde, Laura Lim, Vibhuti Vyas, Christine Brown, S. Forman (2019)
CD19-Targeting CAR-T Cell Therapy in CNS LymphomaBlood
M. Maus, S. Alexander, M. Bishop, Jennifer Brudno, C. Callahan, M. Davila, C. Diamonte, J. Dietrich, J. Fitzgerald, M. Frigault, T. Fry, J. Holter-Chakrabarty, K. Komanduri, Daniel Lee, F. Locke, S. Maude, P. McCarthy, E. Mead, S. Neelapu, T. Neilan, B. Santomasso, E. Shpall, D. Teachey, C. Turtle, T. Whitehead, S. Grupp (2020)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsJournal for Immunotherapy of Cancer, 8
S. Ghafouri, J. Timmerman, Sarah Larson, M. Mead (2020)
Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?Bone Marrow Transplantation, 56
J. Abramson, B. McGree, S. Noyes, Sean Plummer, C. Wong, Yi-Bin Chen, E. Palmer, T. Albertson, J. Ferry, I. Arrillaga-Romany (2017)
Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.The New England journal of medicine, 377 8
K. Dunleavy, W. Wilson (2012)
How I treat HIV-associated lymphoma.Blood, 119 14
Cancer Discov, 8
J. Abramson, M. Palomba, L. Gordon, M. Lunning, Michael Wang, J. Arnason, A. Mehta, E. Purev, D. Maloney, C. Andreadis, A. Sehgal, S. Solomon, N. Ghosh, T. Albertson, Jacob Garcia, A. Kostić, Mary Mallaney, K. Ogasawara, K. Newhall, Yeonhee Kim, Daniel Li, T. Siddiqi (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 396
P. Brown, V. Gondi, S. Pugh, W. Tomé, J. Wefel, T. Armstrong, J. Bovi, C. Robinson, A. Konski, D. Khuntia, D. Grosshans, T. Benzinger, D. Bruner, M. Gilbert, D. Roberge, V. Kundapur, K. Devisetty, Sunjay Shah, K. Usuki, B. Anderson, B. Stea, H. Yoon, Jing Li, N. Laack, T. Kruser, S. Chmura, W. Shi, S. Deshmukh, M. Mehta, L. Kachnic (2020)
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, J. Timmerman, P. Stiff, J. Friedberg, I. Flinn, A. Goy, B. Hill, Mitchell Smith, A. Deol, U. Farooq, P. Mcsweeney, J. Muñoz, I. Avivi, J. Castro, J. Westin, J. Chavez, A. Ghobadi, K. Komanduri, R. Levy, E. Jacobsen, T. Witzig, P. Reagan, A. Bot, J. Rossi, L. Navale, Yi-zhou Jiang, J. Aycock, M. Elias, David Chang, J. Wiezorek, W. Go (2017)
Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell LymphomaThe New England Journal of Medicine, 377
J. Abramson, Kelly Irwin, M. Frigault, J. Dietrich, B. McGree, J. Jordan, A. Yee, Yi-Bin Chen, N. Raje, J. Barnes, Benjamin Davis (2019)
Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphomaCancer, 125
Ian Bickle, Frank Gaillard (2016)
Primary CNS lymphomaRadiopaedia.org
S. Grupp, M. Kalos, D. Barrett, R. Aplenc, David Porter, S. Rheingold, D. Teachey, A. Chew, B. Hauck, J. Wright, Michael Milone, Bruce Levine, Carl June (2013)
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.The New England journal of medicine, 368 16
K. Jhaveri, I. Schlam, N. Holtzman, M. Peravali, P. Richardson, S. Dahiya, V. Malkovska, A. Rapoport (2020)
Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy.Blood advances, 4 23
J. Gust, K. Hay, K. Hay, L. Hanafi, Daniel Li, D. Myerson, D. Myerson, L. Gonzalez-Cuyar, Cecilia Yeung, C. Yeung, W. Liles, M. Wurfel, José López, Junmei Chen, D. Chung, Susanna Harju-Baker, Tahsin Özpolat, Kathleen Fink, S. Riddell, S. Riddell, D. Maloney, D. Maloney, C. Turtle, C. Turtle (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.Cancer discovery, 7 12
(2018)
JCAR015 in ALL: A Root-Cause Investigation.Cancer discovery, 8 1
P. Brown, S. Pugh, N. Laack, J. Wefel, D. Khuntia, C. Meyers, A. Choucair, S. Fox, J. Suh, D. Roberge, V. Kavadi, S. Bentzen, M. Mehta, D. Watkins-Bruner (2013)
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.Neuro-oncology, 15 10
Oncologist, 25
M. Frigault, J. Dietrich, M. Martinez-Lage, M. Leick, Bryan Choi, Z. DeFilipp, Yi-Bin Chen, J. Abramson, J. Crombie, P. Armand, L. Nayak, Christopher. Panzini, Lauren Riley, Kathleen Gallagher, M. Maus (2019)
Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma.Blood
T. El‐Galaly, Chan Cheah, M. Bendtsen, S. Grzegorz, Nowakowski, R. Kansara, K. Savage, J. Connors, H. Laurie, Sehn, N. Goldschmidt, A. Shaulov, U. Farooq, B. Link, M. AndreśJ., Ferreri, T. Calimeri, C. Cecchetti, E. Dann, C. Thompson, T. Inbar, M. Maurer, Inger Gade, M. Juul, W. Jakob, K Hansen, S. Holmberg, T. Larsen, S. Cordua, N. George, Mikhaeel, M. Hutchings, John Seymour, M. Clausen, Daniel, Smith, Stephen Opat, M. Gilbertson, G. Thanarajasingam, D. Villa (2018)
Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.European journal of cancer, 93
Monika Müller, Simon Wandel, R. Colebunders, S. Attia, H. Furrer, M. Egger (2010)
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.The Lancet. Infectious diseases, 10 4
King (2019)
878J Adv Pract Oncol, 10
Z. Arvanitakis, R. Shah, D. Bennett (2019)
Diagnosis and Management of Dementia: Review.JAMA, 322 16
N. Bennani, M. Maurer, L. Nastoupil, M. Jain, J. Chavez, A. Cashen, S. Dahiya, L. Lekakis, P. Reagan, O. Oluwole, J. Mcguirk, A. Deol, A. Sehgal, A. Goy, Brian Hill, K. Vu, C. Andreadis, J. Muñoz, A. Rapoport, J. Vose, D. Miklos, F. Locke, S. Neelapu, Yi Lin (2019)
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T ConsortiumBlood
Gust (2019)
42Ann Neurol, 86
Tongjuan Li, Lei Zhao, Yuanyuan Zhang, Yi Xiao, Di Wang, Liang Huang, Liya Ma, Liting Chen, Songya Liu, Xiaolu Long, Fankai Meng, Xiaojian Zhu, Jia Wei, Bin Xu, Jianfeng Zhou, Xiaoxi Zhou (2020)
CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the BrainFrontiers in Oncology, 10
M. Lionakis, K. Dunleavy, M. Roschewski, B. Widemann, J. Butman, R. Schmitz, Yandan Yang, D. Cole, C. Melani, C. Higham, Jigar Desai, M. Ceribelli, Lu Chen, Craig Thomas, R. Little, J. Gea-Banacloche, S. Bhaumik, M. Stetler-Stevenson, S. Pittaluga, E. Jaffe, John Heiss, N. Lucas, S. Steinberg, L. Staudt, W. Wilson (2017)
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.Cancer cell, 31 6
M. Shiels, G. Copeland, M. Goodman, Janna Harrell, C. Lynch, K. Pawlish, R. Pfeiffer, E. Engels (2015)
Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipientsCancer, 121
R. Weinkove, P. George, N. Dasyam, A. McLellan (2019)
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerationsClinical & Translational Immunology, 8
M. Torre, I. Solomon, Claire Sutherland, S. Nikiforow, D. DeAngelo, R. Stone, H. Vaitkevicius, I. Galinsky, R. Padera, N. Trede, S. Santagata (2018)
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral EdemaJournal of Neuropathology & Experimental Neurology, 77
A. Abbasi, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, R. Elkind, K. Fehn, Alyssa Castro, Yanhua Wang, Olga Derman, Randin Nelson, J. Uehlinger, K. Gritsman, R. Sica, N. Kornblum, I. Mantzaris, A. Shastri, M. Janakiram, M. Goldfinger, A. Verma, I. Braunschweig, Lizamarie Bachier-Rodriguez (2020)
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitisJournal of Hematology & Oncology, 13
J. Pluda, David Venzon, Giovanna Tosato, J. Lietzau, K. Wyvill, David Nelson, Elaine Jaffe, Judith Karp, Samuel Broder, R. Yarchoan (1993)
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 6
J. Gust, O. Finney, Daniel Li, Hannah Brakke, Roxana Hicks, Robert Futrell, Danielle Gamble, Stephanie Rawlings-Rhea, H. Khalatbari, G. Ishak, Virginia Duncan, R. Hevner, M. Jensen, Julie Park, R. Gardner (2019)
Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapyAnnals of Neurology, 86
L. Bowen, A. Nath, Bryan Smith (2018)
CNS immune reconstitution inflammatory syndrome.Handbook of clinical neurology, 152
E. Chong, J. Svoboda, Sunita Nasta, D. Landsburg, N. Winchell, E. Napier, A. Mato, J. Melenhorst, M. Ruella, S. Lacey, Carl June, Stephen Schuster (2018)
Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin LymphomasBlood
N. Abdel-Wahab, Mohsin Shah, M. Lopez-Olivo, M. Suarez‐Almazor (2018)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune DiseaseAnnals of Internal Medicine, 168
E. Chong, J. Melenhorst, S. Lacey, David Ambrose, V. Gonzalez, B. Levine, C. June, S. Schuster (2017)
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.Blood, 129 8
(2018)
Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review, 168
Kathryn Cappell, J. Kochenderfer (2021)
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domainsNature Reviews Clinical Oncology, 18
Grommes (2017)
2410J Clin Oncol, 35
Daniel Lee, B. Santomasso, F. Locke, A. Ghobadi, C. Turtle, Jennifer Brudno, M. Maus, Jae Park, E. Mead, S. Pavletic, W. Go, L. Eldjerou, R. Gardner, N. Frey, K. Curran, K. Peggs, M. Pasquini, J. Dipersio, M. Brink, K. Komanduri, S. Grupp, S. Neelapu (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25 4
B. Santomasso, Jae Park, Darin Salloum, I. Rivière, J. Flynn, E. Mead, E. Halton, Xiuyan Wang, B. Senechal, T. Purdon, J. Cross, Hui Liu, B. Vachha, Xi Chen, L. Deangelis, Daniel Li, Y. Bernal, M. Gonen, H. Wendel, M. Sadelain, R. Brentjens (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.Cancer discovery, 8 8
W. Baker, G. Royer, R. Weiss (1991)
Cytarabine and neurologic toxicity.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 4
Daphne Lo, G. Grossberg (2011)
Use of memantine for the treatment of dementiaExpert Review of Neurotherapeutics, 11
J. Gust, A. Taraseviciute, C. Turtle (2018)
Neurotoxicity Associated with CD19-Targeted CAR-T Cell TherapiesCNS Drugs, 32
B. Reisberg, R. Doody, A. Stöffler, F. Schmitt, S. Ferris, H. Möbius (2003)
Memantine in moderate-to-severe Alzheimer's disease.The New England journal of medicine, 348 14
Safety and efficacy of KTE-C19 in adults with refractory aggressive non-Hodgkin lymphoma
Cellular immunotherapy following chemotherapy in treating patients with recurrent non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia
Secondary central nervous system lymphoma (SCNSL) is associated with poor prognosis and new therapeutic approaches are needed. The pivotal trial that led to US Food and Drug Administration (FDA) approval of axicabtagene ciloleucel excluded patients with SCNSL and human immunodeficiency virus. In this multi-institutional retrospective study, 14 SCNSL patients treated with axicabtagene ciloleucel, 3 of whom had human immunodeficiency virus, experienced rates of severe neurotoxicity and complete response of 32% and 58%, respectively. This is similar to rates observed in the pivotal ZUMA-1 trial that led to the approval of axi-cel at median follow-up of 5.9 months. Chimeric antigen receptor T-cell therapy is potentially a life-saving therapy for SCNSL patients and should not be withheld.
Journal of Immunotherapy – Wolters Kluwer Health
Published: Jun 11, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.